EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
M Solha, NJ Bahlisb, NS Rajec, CL Costellod, B Dholariae, MY Levyf, MH Tomassong, H Dubeh, MA Damoreh, HK Lonh, C Basui, A Skouraj, EM Chank, S Trudell, A Jakubowiakm, MP Chun, C Gasparettoo, A Dalovisiop, M Sebagq, AM Lesokhinr
a Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, United States
b Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
c Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, United States
d Moores Cancer Center, University of California San Diego, La Jolla, United States
e Vanderbilt-Ingram Cancer Center, Nashville, United States
f Department of Medical Oncology, Baylor Scott and White Health, Dallas, United States
g Holden Comprehensive Cancer Center, University of Iowa, Iowa, United States
h Oncology Research and Development, Pfizer, San Diego, United States
i Early Clinical Development, Pfizer, San Diego, United States
j Oncology Research and Development, Pfizer, Pennsylvania, United States
k Oncology Research and Development, Pfizer, San Francisco, United States
l Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
m Department of Medicine, University of Chicago Medical Center, Chicago, United States
n Cross Cancer Institute, Edmonton, Canada
o Department of Medicine, Duke University Cancer Institute, Durham, United States
p Department of Hematology and Oncology, Ochsner Health, Jefferson, United States
q Cedars Cancer Center, McGill University Health Center, Montreal, Canada
r Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, United States
Ver másLido
2781
Vezesque se leu este artigo
1109
Total PDF
1672
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 22 | 9 | 31 |
| 2025 5 | 54 | 12 | 66 |
| 2025 4 | 41 | 17 | 58 |
| 2025 3 | 64 | 19 | 83 |
| 2025 2 | 38 | 23 | 61 |
| 2025 1 | 38 | 26 | 64 |
| 2024 12 | 39 | 15 | 54 |
| 2024 11 | 41 | 30 | 71 |
| 2024 10 | 54 | 42 | 96 |
| 2024 9 | 36 | 19 | 55 |
| 2024 8 | 42 | 25 | 67 |
| 2024 7 | 31 | 18 | 49 |
| 2024 6 | 37 | 37 | 74 |
| 2024 5 | 39 | 35 | 74 |
| 2024 4 | 27 | 20 | 47 |
| 2024 3 | 38 | 25 | 63 |
| 2024 2 | 31 | 24 | 55 |
| 2024 1 | 22 | 14 | 36 |
| 2023 12 | 19 | 23 | 42 |
| 2023 11 | 44 | 32 | 76 |
| 2023 10 | 50 | 40 | 90 |
| 2023 9 | 49 | 26 | 75 |
| 2023 8 | 63 | 35 | 98 |
| 2023 7 | 71 | 20 | 91 |
| 2023 6 | 58 | 23 | 81 |
| 2023 5 | 65 | 31 | 96 |
| 2023 4 | 43 | 13 | 56 |
| 2023 3 | 47 | 34 | 81 |
| 2023 2 | 65 | 34 | 99 |
| 2023 1 | 64 | 36 | 100 |
| 2022 12 | 53 | 39 | 92 |
| 2022 11 | 77 | 36 | 113 |
| 2022 10 | 41 | 34 | 75 |
| 2022 9 | 34 | 30 | 64 |
| 2022 8 | 13 | 17 | 30 |
| 2022 7 | 17 | 26 | 43 |
| 2022 6 | 16 | 24 | 40 |
| 2022 5 | 14 | 25 | 39 |
| 2022 4 | 9 | 21 | 30 |
| 2022 3 | 16 | 18 | 34 |
| 2022 2 | 11 | 16 | 27 |
| 2021 1 | 10 | 16 | 26 |
| 2021 12 | 13 | 13 | 26 |
| 2021 11 | 11 | 25 | 36 |
| 2021 10 | 5 | 12 | 17 |
Mostrar tudo
